Business
Can Cannabis Help Cure Ovarian Cancer? New Research Shows Promise
There is a growing body of evidence by scientists proving that cannabis can either slow the growth of or cause death in certain types of cancer cells.
Conducted by the Cannabis Science Center, the research was led by Dr. Dale “Buck” Buchanan, a researcher and professor of physiology at SIU, whose effort is directed mainly toward prevention of the disease.
“The vast majority of ovarian cancer research is focused toward extending what we call ‘progression-free survival,’” he said. “So it seems misguided to me that the focus of the research is on this incremental increase in life, […] so we’re really interested in prevention.”
What Is Ovarian Cancer?
Sadly, ovarian cancer remains the most common cause of cancer death from gynecologic tumors in the United States, according to the Centers for Disease Control and Prevention (CDC).
Buchanan explained that as a result of the process of ovulation, scar tissue that develops after the egg erupts through the surface of the ovary can go awry, resulting in the development of cancerous tissue.
Do Omega-3 Acids Help With Cancer?
His research proved that Omega-three acids created when flaxseed was introduced into a diet, can prevent the development of ovarian cancer and also minimize its severity. By reducing inflammation and allowing the healing of tissue, Omega-three acids compete with the naturally produced inflammatory proteins within the human body.
“The consequence of this is that it has a 70% reduction in the severity of cancer and a 30% reduction in the incidence, and all we did was introduce flax into their diet,” Buchanan said. “But we know nothing about how it works, so that’s our work.”
What Is The Role Of The Endocannabinoid System?
While examining the effects of introducing flax into the diet, the researchers took a closer look at the system of protein receptors throughout the body that react to internally produced and external cannabinoids, also known as the endocannabinoid system.
According to Didas Roy, a graduate student assisting in the research, the endocannabinoid system has, although still unclear, a role in the production of ovarian cancer.
“So in the endocannabinoid system, there are cannabinoids produced inside our bodies, and they’re binding to specific receptors, one and two,” Roy said. “So two is not that much expressed in the ovary, but receptor one is there in high abundance, and it seems like the expression of those receptors increases in cancer.”
Roy’s focus is currently directed toward a protein called TGF-ß, which is present both in the ovaries and the broader endocannabinoid system.
“We know TGF-ß is also implicated in cancer, so we are trying to see how the both of them are related to each other, who is controlling whom and how they’re contributing to ovarian cancer,” Roy said. “TGF-ß is a family of many, many receptors and ligands, so I’m trying to look at all of them.”
Marijuana & Cancer
Meanwhile, there is a growing body of evidence by scientists proving that cannabis can either slow the growth of or cause death in certain types of cancer cells.
Earlier this year, Cannabotech (CNTC.TA) reported that in experiments conducted on a cell model, the fungus extract eliminated 100% of pancreatic cancer cells relatively selectively and without damaging normal cells. Cannabotech is involved in the development of a botanical drug based on an extract of the Cyathus striatus fungus and a cannabinoid extract from the cannabis plant.
The same Israeli biotech company is behind another cell model study, which showed that its “Integrative-Colon” products killed over 90% of colon cancer cells. The Integrative-Colon products are based on a combination of several cannabinoids from the cannabis plant and various mushroom extracts.
A study conducted by Hadassah Medical Center physicians last year provided a ray of hope to those with breast cancer. The research revealed a sixfold improvement in killing breast cancer cells when using specific Cannabotech’s medical cannabis products in combination with standard oncology treatments and drug protocols, such as chemotherapy, biological and hormonal, over the existing treatment.
Source: https://thefreshtoast.com/news/can-cannabis-help-cure-ovarian-cancer-new-research-shows-promise/
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
Marijuana companies suing US attorney general in federal prohibition challenge
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business1 year agoCan Cannabis Help Seasonal Depression
-
Blogs1 year agoCannabis Art Is Flourishing On Etsy